Posted on Leave a comment

Top Tips When Talking to a Healthcare Provider

daughter explaining elderly mother how using smartphone

Because of lockdowns prompted by the global health crisis, many people still fear visiting hospitals and even private clinics in person. Talking to a healthcare provider is a great way to avoid pandemic-related risk without sacrificing your access to proper healthcare.

Written exclusively for doxyva.com by Aria Covers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

By getting in touch with a healthcare provider, you can get essential medical prescriptions, specific instructions on treating particular conditions, and even practical information on new treatments for COVID-19 patients. Today, the field of telehealth has expanded to include not just home health monitoring devices, but also efficient online communication platforms that make remote diagnosis possible. What can you do to streamline your communication with your healthcare provider when contacting them online?

Get in touch with and get to know the right specialists

Make sure you’re contacting the right people for the job. This will allow you to arrive at a safe and correct medical solution faster. Rather than getting transferred from call-to-call or email-to-email, actively finding the best specialist who can answer your specific inquiries makes the entire process quicker and more convenient for everyone involved. This is particularly crucial in the modern pandemic era, in which there is a massive shortage of health workers, particularly nurses.

Nurses are not only the backbone of the front-line efforts against COVID, they’re also likely to be the first qualified specialists you will be put in touch with by healthcare providers. This demand is why the nursing profession is expected to grow by 7% until 2029. Unfortunately, the bachelor’s and graduate degree programs from brick-and-mortar nursing schools and universities are currently unable to accommodate new students to respond to the demand. But the good news is that the digital migration of education is allowing both traditional and online universities to pick up the slack. In fact, current online RN to BSN degree programs which allow registered nurses to train for in-demand specializations can now be taken and completed 100% through remote work. So if you are looking for specialist advice and get through to a nurse know that they will be fully qualified to answer your concerns and questions. Just note that when you do manage to contact the right specialist, it’s important to remember that their time may be limited, as the shortage has stretched practically all nurses and other health providers thin. This brings us to our next point.

Ask informed questions

You can always turn to Google to find fundamental and objective information on practically any medical or health-related concern or inquiry. Doing this is a good way to further streamline the online consultation process. By coming to an online discussion with your healthcare provider from an informed perspective, they can more efficiently provide you with the right solutions, treatments, prescriptions, or plans. While speaking directly with a healthcare provider is still much safer than scrounging the web for info, a little online research definitely helps. There’s also a variety of legitimate sources of medical information that can be found on the web today. The Centers for Disease Control and Prevention for instance has been quite active at updating its online portal for any questions that people might have about the COVID-19 vaccine. The better you can ask informed questions, the faster you can get useful answers.

Be honest, straightforward, and upfront

If there’s anyone that you should be honest and straightforward with, it’s your healthcare provider. For instance, the more you can tell us about your condition and any related concerns, the better we at D’oxyva can develop your online personalized recovery-oriented program or plan. Having a full and upfront purview of your medical history gives healthcare providers everything they need to provide adequate solutions.

In the era of telehealth, it’s easier than ever to talk to healthcare providers. And by following these aforementioned tips, you can maximize your limited time online with these nurses, doctors, therapists, and other specialists.

physician-recommended, easy to use daily

Why Use D'OXYVA?

Experts say D’OXYVA® can help patients find relief. Overwhelming  medical data shows people with preexisting conditions, including diabetes may experience serious complications with COVID-19.

D’OXYVA significantly helps people and their pets by gently and quickly spraying a patented and patent-pending ultra-purified, supersaturated solution on the skin surface to achieve major health benefits for well over 90% of users.

Experts call D’OXYVA a game-changer biotech. “Studies with D’OXYVA have shown unmatched results in noninvasive wound care,” Dr. Michael McGlamry. Anyone with an underlying condition should know this option is available.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Most Frequently Administered Drugs in the U.S. Are Not What You Think!

medical co2
Currently, the most frequently administered drugs in the United States are medical gases such as NO, O2, and CO2 that have been around in health care for some time and are used daily for many medical purposes in hospitals including anesthesia, therapy and diagnosis, according to the U.S. FDA.
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
A medical gas is defined as one that is manufactured, packaged, and intended for administration to a patient in anesthesia, therapy, or diagnosis. Medical gases are used within hospital settings for many purposes.
The departments that use medical gases in hospitals include operating rooms, per-communicators, recovery rooms, debridement rooms, obstetrics and gynecology wards, ICU wards, and general wards. There are seven kinds of gases commonly used in health care: oxygen, nitrogen, nitrous oxide, argon, helium, carbon dioxide and compressed air.
Carbon makes strong bonds that give drugs their shape and readily releases those bonds, letting molecules emit stored energy, while its ability to maintain four bonds at once makes it the periodic table’s working horse. Carbon dioxide is a so-called ‘gasotransmitter’ inside the body that sends signals to the brain besides balancing the partial pressure of oxygen in blood and the local blood supply, besides affecting other vital functions.
Medically, carbon dioxide (CO2) is typically used for anesthesia and to inflate the abdominal cavity and colon for laparoscopy and colonoscopy. In addition, it is also used for laboratory culture of bacteria (anaerobic bacteria).
According to a Grand View Research Report1, in 2016 the global medical gas market size was valued at USD 7.5 billion and by 2024 is expected to witness a 9.0% compounded annual growth rate (CAGR). An increasing incidence of chronic diseases, an ever-growing geriatric population, and a rising demand for home healthcare and point of care products are some of the major factors behind the growth of the medical gases market.
Therapeutic applications of medical gases are so important that this purpose alone held the largest market revenue in 2016. Aside from pure gases, such as oxygen, the most commonly used medical gas mixtures are Carbon Dioxide-Oxygen mixtures, which in 2016 showed the biggest market profits. These medical gas mixtures are also expected to gain a significant market share owing to their increasing use in therapeutic and diagnostic applications.

The potential growth of CO2 mixtures is probably due to its extensive use for the assessment of chronic respiratory diseases such as asthma or bronchitis… and its use in combination with radiation for cancer treatment. Moreover, CO2 is used for oxygenation and in anesthetic mixtures useful in procedures like renal dialysis, cardio-pulmonary bypass surgery or in the management of chronic respiratory obstruction after the obstruction has been removed.

With a global rise in respiratory diseases and cancer, the demand for medical CO2 mixtures is expected to increase in the near future.

According to renown experts like Judy M. Delp, Ph.D. in physiology and professor at the Florida State University, there are several general positive health effects associated to CO2, namely:

  • It has sedating effects over the central nervous system
  • It increases blood flow through arteriolar/venous dilation, thus improving microcirculation
  • It produces a rightward shift in the O2 dissociation curve, thereby increasing oxygen delivery at the cellular level and leading to better tissue/organ oxygenation
  • It is a fat-dissolving compound.

One of the most important effects of CO2 on the body is that of increased vasodilation and oxygenation. A high CO2 concentration potentiates the S-shaped dissociation curve of hemoglobin (Hb) to release O2 , therefore increasing O2 unloading from hemoglobin from a normal 40% dissociation rate to 70% O2 dissociation rate. This increased O2 unloading results in better tissue oxygenation. Further, it has been shown that increased pCO2 promotes arteriolar dilation in various tissues, and it plays a key role in regulating cerebral blood flow2.

Although there are several ways of delivery, D’OXYVA® uses a non-invasive skin-delivery method of vaporized ultra-purified CO2, which has been shown in quality human clinical studies to be safer than inhalation, a routine delivery method in hospital settings. The CO2 gets mixed with water inside the device, producing an active solution of supersaturated CO2 and water (H2O) vapor that improves skin microcirculation and/or blood circulation after dissolving into the skin3.

Rapid and gentle transdermal delivery with the D’OXYVA light-weight and hand-held device has recorded improving the blood microcirculation or perfusion index (PI) by 33%* on average in all participants. After single 5–minute D’OXYVA® delivery on skin surface lasting results could be already measured 5 minutes afterwards and up to 4 hours4. while increasing O₂ saturation in comparison to controls up to 2 hours after application. Clinical data also showed a consistent significant decrease in systolic and diastolic blood pressure up to 240 minutes after a single treatment with D’OXYVA®. Moreover, transdermal CO2 has shown positive results in wound care in several D’OXYVA® clinical studies, even where other treatment modalities have failed5 while reporting on zero side effects. Finally, experts believe transdermal CO2 successfully improves organ function (pancreas, liver, brain, and kidneys) and general health status in patients with hypertension.

Circularity Healthcare was established with a core mission to radically change the standard of care and improve lives, while demonstrating the emerging concept of the Circular Carbon Economy with the help of influential global strategic relationships. Our pioneering patented and patent-pending biotech called D’OXYVA® (deoxyhemoglobin vasodilator) utilizes mini, single-use cartridges and ultra-purified CO2 molecules filled inside them, which are non-toxic and harmless to our bodies and the environment, making them eco-friendly and fully compliant with federally regulated health and transportation safety guidelines and laws.

Following our company’s guidelines is highly advised when using our products, as your health is our top priority. With D’OXYVA, you’re choosing a clean, tested method that utilizes technology for your benefit. Check out our amazing products now and discover the right method to radically improve your quality of life and feel confident about the solution you’re using.

Carbon dioxide is sourced either naturally from deep underground wells or from capturing atmospheric, industrial and transportation emissions. Check out one of the latest carbon capture technologies from the world’s largest energy company, Aramco by visiting a Better Future.

Warning! Tampering with and misusing gas cartridges and cylinders in any way carries a maximum penalty of up to 5 years in federal prison and a $500,000 fine, with similar laws in place in most countries around the world.

Reference(s)

The history of respiratory protection traces back as far as Pliny the Elder (23-79 AD), a Roman philosopher and naturalist, who made use of loose animal bladder skins to filter dust from being inhaled while crushing cinnabar, which is a toxic, mercuric sulfide mineral used at the time for pigmentation in decorations.
 
The global medical gases and equipment market is exhibiting steady growth with the surge in demand from hospitals, home care settings, pharmaceutical companies, and other healthcare facilities. A recent study by Fact.MR states that the medical gases and equipment market is anticipated to grow at over 8% CAGR during the forecast period between 2020 and 2030.

Bibliography

1. Medical Gas Market Size & Share | Global Industry Report, 2014-2024. https://www.grandviewresearch.com/industry-analysis/medical-gases-market.
2. CV Physiology | Metabolic Mechanisms of Vasodilation. https://www.cvphysiology.com/Blood%20Flow/BF008.
3. Introducing D’OXYVA – What is D’OXYVA? D’OXYVA https://doxyva.com/about-doxyva/.
5. Puruhito, I. et al. D’OXYVA® Medical Device, a Potentially Cost-Efficient and Safe Adjuvant Therapy for Diabetic Ulcers: A Pilot Study. J Vasc Surg (2019).

physician-recommended, easy to use daily

Why Use D'OXYVA?

Experts say D’OXYVA® can help patients find relief. Preliminary medical data shows people with preexisting conditions, including diabetes may experience serious complications with COVID-19.

D’OXYVA significantly helps people and their pets by gently and quickly spraying a patented and patent-pending ultra-purified, supersaturated solution on the skin surface to achieve major health benefits for well over 90% of users.

Experts call D’OXYVA a game-changer biotech. “Studies with D’OXYVA have shown unmatched results in noninvasive wound care,” Dr. Michael McGlamry. Anyone with an underlying condition should know this option is available.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Photomicrography Competition – The Nikon Small World Competition

Retina micro-vessels
Celebrating 46 years of images captured by the light microscope.

Nikon’s Small World is regarded as the leading forum for showcasing the beauty and complexity of life as seen through the light microscope. The Photomicrography Competition is open to anyone with an interest in microscopy and photography. The video competition, entitled Small World In Motion encompasses any movie or digital time-lapse photography taken through the microscope.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

Photomicrography Competition

The Nikon Small World Competition first began in 1975 as a means to recognize and applaud the efforts of those involved with photography through the light microscope. Since then, Small World has become a leading showcase for photomicrographers from the widest array of scientific disciplines.

Source: https://www.nikonsmallworld.com/galleries/photomicrography-competition

physician-recommended easy to use daily

Why Use D'OXYVA?

Expert say D’OXYVA can help COVID-19 patients find relief. Overwhelming medical data shows people with preexisting conditions including diabetes may experience serious complications from COVID-19. D’OXYVA significantly helps people and pets by gently and quickly spraying a patented and patent-pending ultra-purified, supersaturated solution on the skin to achieve major health benefits for well over 90% of users. Experts call D’OXYVA a game changer.

“Studies with D’OXYVA have shown unmatched results in noninvasive wound care,” Dr. Michael McGlamry. Anyone with an underlying condition should know this option is available.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

While coronavirus vaccines race ahead, our treatment options remain mediocre. There are good reasons for that.

Vaccination

Just a year into the pandemic, three vaccines have already been found to protect people from coronavirus infection – the fastest vaccine development process in history by at least four years. The US public will likely start getting shots within weeks. In the last month, Pfizer Moderna, and AstraZeneca have all announced that their coronavirus vaccine candidates were found to be effective in trials.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
Meanwhile, none of the drugs we have for COVID-19 so far are particularly effective.Experts cite several reasons why: Vaccines have received far more funding due to their potential to stop the pandemic, and they’re easier to test in large studies.Yet for people who get sick, treatment options are still far from perfect.The Food and Drug Administration has approved one coronavirus treatment and authorized five others. But for severely ill patients, only one therapy – steroids – has been found to definitively reduce death rates.The therapies authorized for less-serious COVID-19 cases, meanwhile, all belong to the same family: monoclonal antibodies. While promising, these treatments are expensive, difficult to manufacture, and haven’t yet demonstrated efficacy in large trials.There are several reasons our vaccine options have outstripped treatments. The first is cost-effectiveness: While vaccines are expensive and time-consuming to develop, they have the potential to stop the pandemic. Treatments only help those already sick, so are less valuable to governments overall.“I’m not surprised that there’s been more aggressive funding to work with vaccines, because I think, in the end, that’s how we’re going to turn the tide on this,” Taison Bell, an infectious-disease physician at the University of Virginia, told Business Insider.

text: A vial of remdesivir is pictured during a news conference at the University Hospital Eppendorf in Hamburg, Germany, April 8, 2020. Ulrich Perrey/Reuters

Additionally, researchers can conduct vaccine trials on tens of thousands of healthy volunteers, whereas studies about treatments require thousands of sick patients.

And finally, treatments are notoriously difficult to develop for viruses, especially respiratory ones. Scientists have been trying, and failing, to find effective treatments for rhinoviruses – which cause most common colds – since the 1950s.

The juxtaposition was stark: In the same mid-November week, Moderna announced that its vaccine was found to be 94.5% effective, and the World Health Organization announced that it won’t recommend the antiviral drug remdesivir, since it hasn’t been found to lower mortality rates.

Remdesivir is the only coronavirus treatment the FDA has formally approved. Although some studies show it can shorten hospital stays for seriously ill patients, it doesn’t appear to reduce the incidence of death. It’s also expensive, at $2,340 for a standard course.

The FDA has granted emergency authorization to six other coronavirus treatments, including convalescent plasma, corticosteroids, and hydroxychloroquine, though the agency then revoked hydroxychloroquine’s authorization in June.

The most recent drug to get FDA authorization, the monoclonal antibody therapy bamlanivimab, targets the coronavirus’ spike protein to block its entry into cells. But the treatment does not appear to benefit hospitalized patients, according to studies.

“These are sort of things that move the bar a little bit, but none of these are game-changers,” Bell said.

Monoclonal antibody treatments are also hard to manufacture and distribute, according to Bell: They can take up to two weeks to produce in a complex process that can require 10 distinct steps.

Corticosteroids, meanwhile, can lower death rates, and they’re cheap: A standard treatment course of the steroid dexamethasone will likely cost between $10 and $13, according to Michael Rea, the CEO of Rx Savings Solutions. But steroids can have damaging side effects and even make patients vulnerable to other infections, which is why they’re only authorized for patients with severe COVID-19.

a hand holding a blue and white shirt: The world’s eyes are trained on the few companies coming forward with vaccines for coronavirus, but with companies like Pfizer and Moderna getting very close to releasing theirs to the public, and others like Johnson & Johnson’s being paused due to an unexplained illness just when it was starting to gain traction, the question mark around people’s trust in vaccines continues to grow.Besides the conspiracy theories that companies are trying to put chips in humans, or the repeatedly disproved theories that vaccines cause autism, people are concerned about the speed with which these new vaccines are being created, and much of the fear around them comes from not fully understanding how they work. And that goes for vaccines of all sorts!So, click through to read about how regular vaccines work, how COVID-19 vaccines are developing, and what the new RNA technology means for our immunization and the (hopeful) end of this pandemic.

Viruses are hard to treat

Viruses are simply more difficult to target with medications than other illnesses, Bell said.

“Viruses, for the most part, operate inside of our body’s cells, which is much harder to target than, say, bacteria, where most live outside of our body cells and are more readily attacked by antibiotics,” he explained.

Plus, studies of new treatments generally require large numbers of sick patients, whereas vaccine studies can just give shots to healthy volunteers then see who gets sick. Most treatment studies are also messier, since many patients in hospitals often get combinations of different therapies.

Albert Rizzo, chief medical officer for the American Lung Association, said that although it’s unfortunate so many people have gotten COVID-19, the sheer number of patients has accelerated medical researchers’ ability to figure out how best to help people.

“Right now, the medical industry, or healthcare system, has learned a lot more about how to treat patients,” he told Business Insider.

Doctors have learned to avoid ventilators when possible, monitor blood-oxygen levels of high-risk patients, and administer treatments when they’re most effective in the course of an illness, he explained.

a person standing in front of a building: Medical staff wearing full PPE push a stretcher with a deceased patient to a car outside of the COVID-19 intensive care unit at the United Memorial Medical Center on June 30, 2020 in Houston, Texas. Go Nakamura/Getty Images

Vaccines spur the body to annihilate viruses

Vaccines train the body’s own immune system to kill a virus before it can enter too many cells.

Pfizer and Moderna’s vaccines are each than 94% effective, and AstraZeneca’s candidate seems to be 70% effective, on average. Pfizer plans to send out 6.4 million doses of its vaccine within 24 hours of getting regulatory clearance, which could happen by mid-December. Moderna expects to have between 100 and 125 million doses ready in the first quarter of 2021, and 20 million doses in the US by the end of the year.

All three vaccine candidates got some degree of financial backing from Operation Warp Speed, which aims to produce and distribute 300 million vaccine doses in the US by January. The program has awarded more than $12 billion in contracts to spur the rapid development and testing of eight primary vaccine candidates.

But it has only funded three treatments, all of them monoclonal antibodies.

Capped vials used during filling and packaging tests for the large-scale production of AstraZeneca and the University of Oxford's COVID-19 vaccine candidate. VINCENZO PINTO/AFP via Getty Images

Vaccines offer ‘the most benefit for the dollar spent’

The dizzying speed of coronavirus vaccine development is not cause for alarm, according to Rizzo.

“We’re not skipping steps – we actually have better technology,” he said, citing advances in genetic sequencing and mRNA technology. “It’s like saying, why did it take two weeks to cross the Atlantic back in the 1800s? Well, we had to go on a boat. Whereas now you can get across the ocean in several hours.”

Given that, experts say, drugs simply deliver less value than vaccines.

“If I was controlling funding and trying to divert the resources where I think I would get the most benefit for the dollar spent, I would actually develop it towards vaccines,” Bell said.

Rizzo said he is looking forward to more research on several other possible therapies, though. One, infliximab, may help keep the immune system from overreacting to coronavirus. A September article in The Lancet Rheumatology suggested the drug could “have a major impact on the need for ventilation and mortality.”

Baricitinib could also be found to significantly reducing mortality for people with serious cases of COVID-19 once larger trials are conducted. A small, early study found that 17% of patients given the drug died or needed a ventilator, compared with 35% in the control group.

Still, researchers haven’t found a drug that’s cheap, easy to distribute, and meaningfully improves outcomes for patients with less severe symptoms.

“All things considered, I’m most happy that we have multiple vaccine candidates at this point,” Bell said.

FEATURED

Blog Posts

physician-recommended, easy to use daily

Why Use D'OXYVA?

Experts say D’OXYVA® can help patients find relief. Overwhelming published medical data shows people with preexisting conditions, including diabetes may experience serious complications with COVID-19. D’OXYVA significantly helps people and their pets by gently and quickly spraying a patented and patent-pending ultra-purified, supersaturated solution on the skin surface to achieve major health benefits for well over 90% of users. Experts call D’OXYVA a game-changer biotech.

“Studies with D’OXYVA have shown unmatched results in noninvasive wound care,” Dr. Michael McGlamry. Anyone with an underlying condition should know this option is available.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

U.S. Transdermal Drug Delivery System Market Size, Share & Trends Analysis Report By Technology (Active, Passive), By Application (Hormone, Cardiovascular, Neurodegenerative, CNS, Pain Management), And Segment Forecasts, 2019 – 2026

Skin
The U.S. transdermal drug delivery system market size was valued at USD 14.7 billion in 2018 and is expected to grow at a compound annual growth rate (CAGR) of 9.5% from 2019 to 2026. Increasing demand for painless drug delivery, coupled with rising demand for self-administration of drugs, is anticipated to fuel market growth. The market is also propelled by ongoing technological advancements in the field. Smart patches, for instance, allow auto-injection of medication and help in monitoring various body parameters. They also enable the transmission of patient-generated data, thereby improving timing and accuracy of drug administration.
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

U.S. transdermal drug delivery system market

According to data by the Center for Disease Control and Prevention (CDC), nearly 6 in every 10 American adults have a chronic disease, while 4 in 10 American adults have more than one chronic disease. The high prevalence of chronic disorders is anticipated to fuel the market for transdermal drug delivery systems. Cardiovascular disorders, diabetes, and Alzheimer’s are some of the main chronic conditions affecting U.S. citizens. These conditions require around the clock monitoring and frequent dose administration, thus facilitating market growth.

Introduction of microneedles patches is anticipated to drive the market. This can be attributed to various benefits of microneedle patches such as rapid onset of action, improved efficacy and skin permeability, self-administration, and improved patient compliance. Furthermore, microneedle patches are able to bypass the stratum corneum and ensure 100% delivery of the loaded drug into the upper dermis or epidermis layer without any pain. These advantages will ensure product demand.

On the down side, high costs associated with development of novel drug-patch combination is anticipated to limit investments in transdermal drug delivery systems. For instance, according to the CEO of Noven Pharmaceuticals, the cost of developing a novel molecule-patch combination is nearly USD 2 billion while the cost of developing a generic transdermal patch is less than 5% of the cost of a novel patch.

Source: https://www.grandviewresearch.com/industry-analysis/us-transdermal-drug-delivery-system-market

FEATURED

Blog Posts

physician-recommended, easy to use daily

Why Use D'OXYVA?

Increasing demand for painless drug delivery, coupled with rising demand for self-administration of drugs, is anticipated to fuel market growth. D’OXYVA® (deoxyhemoglobin vasodilator) is the only fully non-invasive, non-irritating, non-opioid, and completely painless, over-the-skin delivery nerve stimulant and microcirculatory solution with over seven years of industry-leading research results.

D’OXYVA® has been demonstrating for years that it does not break the skin’s barrier, while it provides exceptional quality of life and health benefits quickly and affordably. In short, based on current leading neurology, immunology, microvascular, and cellular oxygenation science, D’OXYVA® is leading the field by:

✔ Significantly lowering the risk of diabetes and cardiovascular complications.

✔ Providing complete significant improvement of difficult wounds together with major pain relief and improved quality of life.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

We have bad news about one of the most promising new coronavirus drugs

coronavirus vaccine

New coronavirus cases are surging yet again, and thousands of people are dying every week. But the world has come a long way since the early days of the pandemic when it comes to treatments. The virus is spreading like wildfire, as many people are failing to observe the safety measures that can reduce transmission. The more people get infected, the more people will die. But doctors are able to save more lives than before thanks to some therapies that can prevent COVID-19 complications and speed up recovery.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
  • A promising drug being developed to treat COVID-19 failed to show efficacy with severe coronavirus cases.
  • Eli Lilly announced that it has terminated a study evaluating the efficacy of the monoclonal antibody drug in hospitalized patients.
  • ”Bamlanivimab [LY-CoV555] is unlikely to help hospitalized COVID-19 patients recover from this advanced stage of their disease,” the company said in its announcement.
  • Lilly continues to study the drug in other trials and has already requested an emergency use authorization to treat mild to moderate cases of COVID-19.

In search of a coronavirus cure, researchers have taken one of the three possible avenues. Some came up with vaccine candidates, and a vaccine might be available to at-risk people by the end of the year. Others repurposed existing drugs for COVID-19 — remdesivir, dexamethasone, and blood thinners are examples that have shown a degree of efficacy. And others are developing brand new drugs, including a type of medicine that should work quite well against the new pathogen. Those are the monoclonal antibody drugs that act much like a very potent plasma transfusion, offering the recipient a high dose of neutralizing antibodies that should block the virus from infecting cells. Monoclonal antibodies can clear the virus or even theoretically provide temporary coronavirus immunity to healthy people. But as promising as these drugs might sound, we’ve just learned they have limitations, and they might not work in the cases that matter most.

Several companies are working on antibody drugs around the world, but two of them are better known than others. Regeneron has a two-antibody cocktail that President Trump received during his COVID-19 recovery. The company has already applied for emergency use authorization (EUA) with the FDA. Eli Lilly is the second, as the company also applied for an EUA even before Regeneron’s announcement. But Eli Lilly revealed a few days ago that it had to halt one of the clinical trials it’s conducting because of a mysterious side effect that wasn’t detailed to the press. The study was paused out of “an abundance of caution” on October 13th.

The National Institutes of Health, a sponsor of the trial, said on Monday that the antibody treatment posed no significant safety risk for patients, according to NPR. But Eli Lilly researchers concluded that the drug couldn’t help patients who are already experiencing severe COVID-19 complications. ”Bamlanivimab [the LY-CoV555 monoclonal antibody] is unlikely to help hospitalized COVID-19 patients recover from this advanced stage of their disease,” the company said.

Lilly combined the drug with remdesivir for this particular stage of the trial. President Trump received a similar combination of meds when he had COVID-19 a few weeks ago. However, Trump got the Regeneron cocktail first before he received the remdesivir regimen, and he also wasn’t experiencing any severe complications at the time.

This particular Lilly trial has been terminated, in what seems to be an unexpected blow for this particular COVID-19 therapy. However, we’ve seen other therapies fail in trials, including hydroxychloroquine, tocilizumab, and lopinavir/ritonavir. Most recently, the World Health Organization concluded that remdesivir can’t prevent COVID-19 deaths. But other studies show that the antiviral can be helpful if administered early in the illness. Furthermore, the plasma studies available so far also showed they could benefit patients if transfusions are rich in potent antibodies, and if they’re administered soon after hospitalization. All hope is not lost because the same might apply to Eli Lilly’s monoclonal antibody drug — it could prove to be a very effective COVID-19 therapy when administered early on.

Lilly will continue to run other trials. The company remains “confident … that bamlanivimab monotherapy may prevent progression of the disease for those earlier in the course of COVID-19.” While Lilly’s ACTIV-3 trial was halted, the various other studies might yield better results. The company already used data from a study of non-hospitalized patients with mild COVID-19 (BLAZE-1) to request EUA to treat mild to moderate illnesses in high-risk patients.

While Eli Lilly failed to prove the drug’s efficacy against severe COVID-19 cases, other monoclonal antibody studies might have different results. All the companies developing monoclonal antibody drugs for COVID-19 make use of different antibodies as well as various antibody combinations.

FEATURED

Blog Posts

physician-recommended, easy to use daily

Why Use D'OXYVA?

Increasing demand for painless drug delivery, coupled with rising demand for self-administration of drugs, is anticipated to fuel market growth. D’OXYVA® (deoxyhemoglobin vasodilator) is the only fully non-invasive, non-irritating, non-opioid, and completely painless, over-the-skin delivery nerve stimulant and microcirculatory solution with over seven years of industry-leading research results.

D’OXYVA® has been demonstrating for years that it does not break the skin’s barrier, while it provides exceptional quality of life and health benefits quickly and affordably. In short, based on current leading neurology, immunology, microvascular, and cellular oxygenation science, D’OXYVA® is leading the field by:

Significantly lowering the risk of diabetes and cardiovascular complications.

Providing complete significant improvement of difficult wounds together with major pain relief and improved quality of life.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Diabetes drug recalled over excess levels of cancer-causing agent

Heads up, consumers: A diabetes drug is facing recall because the medication contains excess levels of a cancer-causing agent, the U.S. Food and Drug Administration (FDA) announced this week.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

Marksans Pharma Limited, a pharmaceutical company in India, announced an expanded recalled of its Metformin hydrochloride extended-release tablets, a drug used to help those who suffer from type 2 diabetes to lower their blood glucose levels. The recall, which was initially announced in June, was expanded on Monday to include an additional 76 unexpired lots of the medication.

An example of the recalled medication. (FDA)

“Marksans performed N-Nitrosodimethylamine (NDMA) testing of unexpired identified marketed lots and observed that NDMA content in some lots is exceeding the acceptable Daily Intake Limit (ADI) of 96ng/day, therefore, out of an abundance of caution, an additional 76 lots are being recalled,” the FDA said when announcing the recall.

NDMA is a “probable human carcinogen,” meaning it’s a substance that can lead to cancer, per the FDA.

“NDMA is a known environmental contaminant found in water and foods, including meats, dairy products and vegetables. Marksans Pharma Limited has not received any reports of adverse events that have been related to this recall,” the FDA said.

The recall impacts metformin tablets between 500 mg and 750 mg. The tablets were sold under the brand name Time-Cap Labs, Inc., according to the announcement.

The following products have been called back:

Metformin Hydrochloride Extended-Release Tablets, USP 500mg:

90 counts: 49483-623-09

100 counts: 49483-623-01

500 counts: 49483-623-50

1000 counts: 49483-623-10

Metformin Hydrochloride Extended-Release Tablets, USP 750mg:

100 counts: 49483-624-01

The 500 mg tablets are debossed with “101” on one side and are plain on the other. The 750 mg tablets, meanwhile, are also debossed with “102” on one side and are plain on the other, per the FDA.

“Consumers taking these recalled product lots of Metformin ER Tablets should continue taking it until a doctor or pharmacist gives them a replacement or a different treatment option. It could be dangerous for patients with type 2 diabetes to stop taking their metformin without first talking to their health care professional,” the FDA warned. The consumer “should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.”

physician-recommended easy to use daily

Why Use D'OXYVA?

D’OXYVA® (deoxyhemoglobin vasodilator) is a validated microcirculation and nerve stimulant for people suffering from the damaging effects of moderate to advanced neuropathy.

Subjects suffering from high blood sugar have reported noticeable neuropathy pain relief only minutes after the D’OXYVA solution protocol, including long-term blood sugar level improvements in just a few weeks.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Children born at high altitudes may be stunted in growth and development, study finds

D'OXYVA for Kids

Children born at 5,000 feet or more above sea level are typically smaller at birth and more likely to remain stunted than those born at lower altitudes, according to new worldwide research published Monday.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
This was true even if the children were born into “ideal-home environments” defined as having good health coverage, higher living conditions and highly educated mothers, the study found, which meant stunting was unlikely to be due to common risk factors such as poor diet and disease.

Growth declined as altitude grew

Children living in ideal home environments grew at rates deemed standard by the World Health Organization until they lived at around 500 meters (1,650 feet) above sea level, the study found. At that altitude and higher, children’s height-for-age scores began to decrease.
At levels of 1,500 meters, or approximately 5,000 feet, above sea level, children were “born at shorter length and remained on a lower growth trajectory” than children who lived in cities at lower sea levels, according to the study published Monday in JAMA Pediatrics.
Prior research has shown growing shorter and slower at higher altitudes can lead to an increased risk of cognitive deficits and metabolic developmental impairments tied to chronic diseases in later life.

A worldwide study

The study looked at height-for-age data for more than 950,000 children in 59 countries.
“More than 800 million people live at 1,500 meters above sea level or higher, with two-thirds of them in Sub-Saharan Africa, and Asia,” said study co-author Kalle Hirvonen, a senior research fellow at the International Food Policy Research Institute, in a statement.
However, there are a number of cities in the United States that fall above 5,000 feet, including Butte, Montana; Cheyenne, Jackson and Laramie, Wyoming; Flagstaff, Arizona; Las Vegas, Albuquerque and Santa Fe, New Mexico; Mammoth Lake, Big Bear Lake and South Lake Tahoe in California; and about 37 cities in Colorado, among others.
In fact, Aspen, Breckenridge and Telluride in Colorado and Santa Fe in New Mexico are all above 7,000 feet above sea level.

Pregnancy highest risk

The study found most of the risk was in the period leading up to and immediately after birth and may be due to lower oxygen levels at higher altitudes.
“Pregnancies at high-altitudes are characterized by chronic hypoxia, or an inadequate supply of oxygen, which is consistently associated with a higher risk of fetal growth restriction,” Hirvonen said.
It was thought that genetic adaption to residing at high altitude over multiple generations might mitigate the stunting, but the study did not show that, Hirvonen said.

“After birth, the growth curve for children in areas 1,500 (meters) or more above sea level was consistently lower, implying limited catch-up to growth levels of children residing in areas lower than 1,500 (meters) above sea level,” the study found.
The results should educate health professionals to more closely work with pregnant women to control the effects of high altitude on the fetus, the study authors said.
“A first step is to unravel the complex relationship linking altitude, hypoxia and fetal growth to identify effective interventions,” said study co-author Kaleab Baye director of the Center for Food Science and Nutrition in Addis Ababa, Ethiopia.
“If children living at altitude are, on average, more stunted than their peers at sea level, then a more significant effort to address high altitude stunting is needed,” Hirvonen said.

FEATURED

Blog Posts

physician-recommended, easy to use daily

Why Use D'OXYVA?

Experts say D’OXYVA® can help patients find relief. Overwhelming medical data shows people with preexisting conditions, including diabetes may experience serious complications with COVID-19.

D’OXYVA significantly helps people and their pets by gently and quickly spraying a patented and patent-pending ultra-purified, supersaturated solution on the skin surface to achieve major health benefits for well over 90% of users.

Experts call D’OXYVA a game-changer biotech. “Studies with D’OXYVA have shown unmatched results in noninvasive wound care,” Dr. Michael McGlamry. Anyone with an underlying condition should know this option is available.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Southeast Asia Detects Mutated Virus Strain Sweeping the World

Southeast Asia is facing a strain of the new coronavirus that the Philippines, which faces the region’s largest outbreak, is studying to see whether the mutation makes it more infectious. The strain, earlier seen in other parts of the world and called D614G, was found in a Malaysian cluster of 45 cases that started from someone who returned from India and breached his 14-day home quarantine. The Philippines detected the strain among random Covid-19 samples in the largest city of its capital region.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

The mutation “is said to have a higher possibility of transmission or infectiousness, but we still don’t have enough solid evidence to say that that will happen,” Philippines’ Health Undersecretary Maria Rosario Vergeire said in a virtual briefing on Monday.

The strain has been found in many other countries and has become the predominant variant in Europe and the U.S., with the World Health Organization saying there’s no evidence the strain leads to a more severe disease. The mutation has also been detected in recent outbreaks in China.

There’s no evidence from the epidemiology that the mutation is considerably more infectious than other strains, said Benjamin Cowling, head of epidemiology and biostatistics at the University of Hong Kong. “It’s more commonly identified now than it was in the past, which suggests that it might have some kind of competitive advantage over other strains of Covid-19,” he said.

As Southeast Asian countries take various steps to prevent a resurgence while reopening limited travel, they struggle with people breaching quarantine rules after returning from overseas as well as false negative test results at borders.

The man who returned from India had tested negative when he arrived in Malaysia. He has since been sentenced to five months in prison and fined for breaching quarantine.

People’s Cooperation

“People need to be wary and take greater precautions because this strain has now been found in Malaysia,” the country’s Director-General of Health Noor Hisham Abdullah wrote in a Facebook post, saying the strain can make it 10 times more infectious without citing a study. “The people’s cooperation is very needed so that we can together break the chain of infection from any mutation.”

The strain “might be a little bit more contagious. We haven’t yet got enough evidence to evaluate that, but there’s no evidence that it’s a lot more contagious,” University of Hong Kong’s Cowling said.

Noor Hisham warned that the strain could mean existing studies on vaccines may be incomplete or ineffective against the mutation. That’s even as a paper published in Cell Press said the mutation is unlikely to have a major impact on the efficacy of vaccines currently being developed.

While Malaysia has largely managed to prevent a resurgence of the virus seen elsewhere in the world, the number of new cases found in the country has been picking up. The country reported 26 new cases on Saturday, the most since July 28.

Confirmed cases in the Philippines have surged 76% from the end of July to a total of 164,474 as of Monday. It overtook Indonesia more than a week ago to become the country with the largest outbreak in Southeast Asia.

— With assistance by Clarissa Batino, and Jason Gale

Source

https://www.bloomberg.com/news/articles/2020-08-17/malaysia-detects-virus-strain-that-s-10-times-more-infectious

FEATURED

Blog Posts

physician-recommended, easy to use daily

Why Use D'OXYVA?

Experts say D’OXYVA® can help patients find relief. Overwhelming medical data shows people with preexisting conditions, including diabetes may experience serious complications with COVID-19.

D’OXYVA significantly helps people and their pets by gently and quickly spraying a patented and patent-pending ultra-purified, supersaturated solution on the skin surface to achieve major health benefits for well over 90% of users.

Experts call D’OXYVA a game-changer biotech. “Studies with D’OXYVA have shown unmatched results in noninvasive wound care,” Dr. Michael McGlamry. Anyone with an underlying condition should know this option is available.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

About 47% of US adults have at least one underlying medical condition that may put them at a higher risk for severe Covid-19 outcomes (CDC)

Older adults and those with chronic obstructive pulmonary disease, heart disease, diabetes, chronic kidney disease, and obesity are at higher risk for severe COVID-19–associated illness.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

What is added by this report?

The median model-based estimate of the prevalence of any of five underlying medical conditions associated with increased risk for severe COVID-19–associated illness among U.S. adults was 47.2% among 3,142 U.S. counties. The estimated number of persons with these conditions followed population distributions, but prevalence was higher in more rural counties.

What are the implications for public health practice?

The findings can help local decision-makers identify areas at higher risk for severe COVID-19 illness in their jurisdictions and guide resource allocation and implementation of community mitigation strategies.

Risk for severe coronavirus disease 2019 (COVID-19)–associated illness (illness requiring hospitalization, intensive care unit [ICU] admission, mechanical ventilation, or resulting in death) increases with increasing age as well as presence of underlying medical conditions that have shown strong and consistent evidence, including chronic obstructive pulmonary disease, cardiovascular disease, diabetes, chronic kidney disease, and obesity (14). Identifying and describing the prevalence of these conditions at the local level can help guide decision-making and efforts to prevent or control severe COVID-19–associated illness. Below state-level estimates, there is a lack of standardized publicly available data on underlying medical conditions that increase the risk for severe COVID-19–associated illness. A small area estimation approach was used to estimate county-level prevalence of selected conditions associated with severe COVID-19 disease among U.S. adults aged ≥18 years (5,6) using self-reported data from the 2018 Behavioral Risk Factor Surveillance System (BRFSS) and U.S. Census population data. The median prevalence of any underlying medical condition in residents among 3,142 counties in all 50 states and the District of Columbia (DC) was 47.2% (range = 22.0%–66.2%); counties with the highest prevalence were concentrated in the Southeast and Appalachian region. Whereas the estimated number of persons with any underlying medical condition was higher in population-dense metropolitan areas, overall prevalence was higher in rural nonmetropolitan areas. These data can provide important local-level information about the estimated number and proportion of persons with certain underlying medical conditions to help guide decisions regarding additional resource investment, and mitigation and prevention measures to slow the spread of COVID-19.

BRFSS is an annual, random-digit–dialed landline and mobile telephone survey of noninstitutionalized U.S. adults aged ≥18 years in all 50 states, DC, and U.S. territories. BRFSS collects self-reported information on selected health behaviors and conditions. Overall, 437,500 persons participated in the 2018 BRFSS survey, with a median weighted response rate of 49.9%.*

The underlying medical conditions included in these prevalence estimates were selected using the subset of the list of conditions with the strongest and most consistent evidence of association with higher risk for severe COVID-19–associated illness on CDC’s website as of June 25, 2020 (2) and for which questions on the BRFSS aligned. These included chronic obstructive pulmonary disease (COPD), heart conditions, diabetes mellitus, chronic kidney disease (CKD), and obesity (defined as body mass index [BMI] of ≥30 kg per m2). Conditions from the list of those with mixed and limited evidence§ of association with increased risk for severe COVID-19 illness were not included (2). An analysis of U.S. COVID-19 patient surveillance data found that hospitalizations were six times higher, ICU admissions five times higher, and deaths 12 times higher among patients with underlying medical conditions, compared with those without (4); however, that analysis included a narrower definition of obesity (BMI ≥40 kg per m2), and some, but not all conditions in both the strongest and most consistent evidence and mixed and limited evidence lists.

BRFSS respondents were classified as having an underlying medical condition if they answered “yes” to any of the following questions: “Have you ever been told by a doctor, nurse, or other health professional that you have COPD, emphysema, or chronic bronchitis; heart disease (angina or coronary heart disease, heart attack, or myocardial infarction); diabetes; or chronic kidney disease?” Respondent-reported height and weight were used to calculate BMI; respondents with BMI ≥30 kg per m2 were considered to have obesity. A created variable captured persons having any of these conditions.

Nationwide estimates of underlying medical conditions were weighted to adjust for survey design. For county-level prevalence, estimates of each and of any condition were generated using a multilevel regression and poststratification approach (5) for 3,142 counties in all 50 states and DC. This approach has been validated in comparison with direct BRFSS survey estimates and local surveys for multiple chronic disease measures at state and county levels (5,6). Briefly, a multilevel regression model was constructed for each outcome using individual-level age, gender, race/ethnicity,** and educational-level†† data from the 2018 BRFSS, and data on county-level percentage of the adult population living at <150% of the poverty level from the 2014–2018 American Community Survey (ACS), a survey sent to about 3.5 million addresses each month that asks about topics not included on the decennial census, including education and employment. The model parameters were applied to 2018 Census county-level population estimates by age, gender, and race/ethnicity to calculate the predicted probability of each outcome. Because the U.S. Census Bureau does not provide county-level population data for education level by age, sex, and race/ethnicity, a bootstrapping approach§§ was used to impute it. The estimated prevalence was obtained by multiplying the probability by the total population by county. Model-based estimates for any condition were validated by comparing them with the weighted direct survey estimates from counties with sample size ≥500 (213) in BRFSS; the Pearson correlation coefficient was 0.89. The county-level estimates of having any underlying medical condition were categorized into six county urban/rural classifications using CDC’s National Center for Health Statistics definitions (large central metro/city, large fringe metro/suburb, medium metro, small metro, micropolitan, noncore/rural) (7). The overall weighted direct survey estimates were conducted using SUDAAN (version 11; RTI International), and other analyses were conducted using SAS (version 9.4; SAS Institute).

The nationwide prevalence of any of the five underlying medical conditions among adults aged ≥18 years was 40.7% (95% confidence interval [CI] = 40.4%–41.0%) (Table 1). The overall weighted prevalences of these conditions were 30.9% (obesity), 11.4% (diabetes), 6.9% (COPD), 6.8% (heart disease), and 3.1% (CKD).

TABLE 1. Nationwide and model-based county-level (n = 3,142) estimates of prevalence and number of adults aged ≥18 years with selected underlying medical conditions that might increase risk for severe COVID-19–associated illness — United States, 2018Return to your place in the text
Selected underlying medical condition*Nationwide prevalence† % (95% CI)Median county prevalence§ % (range)Median county no. of adults† (range)
Any40.7 (40.4, 41.0)47.2 (22.0–66.2)9,743 (41–2,877,316)
Obesity (BMI ≥30 kg/m2)30.9 (30.6, 31.2)35.4 (15.2– 49.9)7,174 (25–2,097,906)
Diabetes mellitus11.4 (11.2, 11.6)12.8 (6.1–25.6)2,742 (11–952,335)
COPD6.9 (6.7, 7.0)8.9 (3.5–19.9)1,962 (7–434, 075)
Heart disease6.8 (6.7, 7.0)8.6 (3.5–15.1)1, 811 (7–434,790)
Chronic kidney disease3.1 (3.0, 3.3)3.4 (1.8–6.2)717 (3–237,766)

Abbreviations: BMI = body mass index; CI = confidence interval; COPD = chronic obstructive pulmonary disease; COVID-19 = coronavirus disease 2019.
* Diabetes mellitus includes both type 1 and type 2 diabetes. COPD includes emphysema and chronic bronchitis. Heart disease includes angina or coronary heart disease, and heart attack or myocardial infarction.
† Weighted direct estimates from the Behavioral Risk Factor Surveillance System, 2018.
§ Prevalence and number of adults estimated for 3,142 counties using a multilevel regression and poststratification approach applied to 2018 Behavioral Risk Factor Surveillance System data.

Among 3,142 counties, the median estimated (modeled) county prevalence of any underlying medical condition was 47.2% (range = 22.0%–66.2%); obesity, 35.4% (range = 15.2%–49.9%); diabetes, 12.8% (range = 6.1%–25.6%); COPD, 8.9% (range = 3.5%–19.9%); heart disease, 8.6% (range = 3.5%–15.1%); and CKD, 3.4% (range = 1.8%–6.2%) (Table 1).

Counties with the highest prevalences of any condition were concentrated in Southeastern states, particularly in Alabama, Arkansas, Kentucky, Louisiana, Mississippi, Tennessee, and West Virginia, as well as some counties in Oklahoma, South Dakota, Texas, and northern Michigan, among others (Figure) (Supplementary Table, https://stacks.cdc.gov/view/cdc/90519). The estimated number of adults with any condition generally followed the population distribution, with higher estimated numbers of persons with any underlying medical conditions in more highly populated areas.

FIGURE. Model-based estimates of U.S. prevalence (A) and number (B) of adults aged ≥18 years with any selected underlying medical condition,* by county — United States, 2018

The figure is map showing model-based estimates of U.S. prevalence (A) and number (B) of adults aged ≥18 years with any selected underlying medical condition, by county, in the United States, in 2018.

* Selected underlying conditions include chronic obstructive pulmonary disease, emphysema, or chronic bronchitis; heart disease (angina or coronary heart disease, heart attack, or myocardial infarction); diabetes; chronic kidney disease; or obesity (body mass index ≥30 kg/m2).

The estimated median prevalence of any condition generally increased with increasing rurality, ranging from 39.4% in large central metro counties to 48.8% in noncore counties (Table 2); the estimated median number of persons with any underlying condition ranged from 4,300 in noncore counties to 301,744 in large central metro counties.

TABLE 2. Model-based estimates of prevalence and number of persons aged ≥18 years with any select underlying medical condition, by urban/rural county classification — United States, 2018Return to your place in the text
County classification*No. of countiesMedian county prevalence % (range)Median county no. of persons (range)
Metropolitan
Large central metro†6839.4 (23.9–48.1)301,744 (43,770–2,877,316)
Large fringe metro§36843.9 (26.4–56.9)34,221 (1,611–725,284)
Medium metro¶37245.5 (22.0–61.7)33,687 (659–332,209)
Small metro**35845.8 (27.8–62.2)26,683 (41–87,153)
Nonmetropolitan
Micropolitan††64147.8 (24.3–64.6)13,979 (176–59,820)
Noncore§§1,33548.8 (26.8–66.2)4,300 (47–29,469)

* Based on 2013 Urban-Rural Classification Scheme for Counties from the National Center for Health Statistics, CDC.
† Large central metro counties in metropolitan statistical areas (MSAs) of 1 million population that 1) contain the entire population of the largest principal city of the MSA, or 2) are completely contained within the largest principal city of the MSA, or 3) contain ≥250,000 residents of any principal city in the MSA.
§ Large fringe metro counties in MSA of ≥1 million population that do not qualify as large central.
¶ Medium metro counties in MSA of 250,000–999,999 population.
** Small metro counties are counties in MSAs of <250,000 population.
†† Micropolitan counties in MSAs.
§§ Noncore counties not in MSAs.

Discussion

Three recent studies have reported that underlying medical conditions are highly prevalent among U.S. COVID-19 patients requiring hospitalization and ICU admission (3,4,8). In this report, the median county prevalence of any of five underlying medical conditions that increase the risk for severe COVID-19–associated illness was 47.2%, and prevalences were higher in counties in the southeastern United States and in more rural counties. These county level estimates can be used together with data on hospitalizations, ICU admissions, and ventilator use among COVID-19 patients with underlying conditions when planning for mitigation efforts and additional resource investment, including hospital beds, staffing, ventilators, and other medical supplies that might be needed to treat persons with underlying medical conditions, should they become ill with COVID-19.

The percentage of the population (prevalence) and the estimated numbers of adults with underlying medical conditions provide information for planning and have implications for health care resource utilization. Areas with comparatively lower prevalences but large populations, such as metropolitan areas, might still have large numbers of persons with underlying medical conditions at increased risk for severe COVID-19 illness. Conversely, areas with smaller populations but a comparatively higher prevalence of persons with underlying medical conditions might also have substantial need for additional resources to treat severe COVID-19 illness. Health care in rural counties is often underresourced,¶¶ and rural communities might have limited access to adequate care, which could further increase risk for poor COVID-19–associated outcomes. Prevalence estimates help highlight counties with a higher relative need for resources, whereas estimates of numbers of persons with underlying medical conditions help identify overall need by county; both can help decision-makers predict resource needs and develop resource allocation plans.

The findings in this report are subject to at least five limitations. First, estimates were based on BRFSS data and subject to survey biases such as nonresponse, social desirability, and recall and knowledge of having a particular condition. Second, BRFSS data do not include all underlying medical conditions that might increase risk for severe COVID-19 illness, such as sickle cell disease, or information on organ transplant or disease severity. Third, some of the underlying medical conditions included in BRFSS might not exactly capture those conditions with the strongest and most consistent evidence such as specific heart conditions (e.g., cardiomyopathies and heart failure) or specific type of diabetes. Further, because COVID-19 is a novel disease and information regarding risk factors for severe illness is evolving, additional underlying medical conditions might be added in the future (as an example, cancer was added to the list after these analyses were conducted). Fourth, BRFSS data are collected for noninstitutionalized civilian persons and exclude populations that might be particularly vulnerable to severe COVID-19 illness, including those living in long-term care facilities and incarcerated populations, and might therefore not be representative for those groups. Finally, these estimates might be imprecise because of the multilevel regression modeling process and county-level population estimation.

These findings can be used by state and local decision-makers to help identify areas at higher risk for severe COVID-19–associated illness because of underlying medical conditions and guide resource allocation and implementation of prevention and mitigation strategies. Future analyses could include weighting the contribution of each underlying medical condition according to the risk for severe COVID-19–associated outcomes, as well as identifying and incorporating other aspects of vulnerability to both infection and severe outcomes to better estimate the number of persons at increased risk for COVID-19. These findings highlight the prevalence of underlying medical conditions at the local (county) level that are important causes of morbidity and mortality on their own and increase risk for severe COVID-19–associated illness. These findings also emphasize the importance of prevention efforts to reduce the prevalence of these underlying medical conditions and their risk factors such as smoking, unhealthy diet, and lack of physical activity.

Source

https://www.cdc.gov/mmwr/volumes/69/wr/mm6929a1.htm

FEATURED

Blog Posts

physician-recommended, easy to use daily

Why Use D'OXYVA?

Experts say D’OXYVA® can help patients find relief. Overwhelming medical data shows people with preexisting conditions, including diabetes may experience serious complications with COVID-19.

D’OXYVA significantly helps people and their pets by gently and quickly spraying a patented and patent-pending ultra-purified, supersaturated solution on the skin surface to achieve major health benefits for well over 90% of users.

Experts call D’OXYVA a game-changer biotech. “Studies with D’OXYVA have shown unmatched results in noninvasive wound care,” Dr. Michael McGlamry. Anyone with an underlying condition should know this option is available.

Reduce unwanted doctor visits, recommended and ranked top by experts!